Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2000 | 1 |
2002 | 2 |
2024 | 0 |
Search Results
3 results
Results by year
Filters applied: . Clear all
Page 1
Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL.
Cancer Gene Ther. 2002 Feb;9(2):164-72. doi: 10.1038/sj.cgt.7700420.
Cancer Gene Ther. 2002.
PMID: 11857034
Intracellular Fas ligand expression causes Fas-mediated apoptosis in human prostate cancer cells resistant to monoclonal antibody-induced apoptosis.
Hyer ML, Voelkel-Johnson C, Rubinchik S, Dong J, Norris JS.
Hyer ML, et al.
Mol Ther. 2000 Oct;2(4):348-58. doi: 10.1006/mthe.2000.0139.
Mol Ther. 2000.
PMID: 11020350
Free article.
Item in Clipboard
Downregulation of c-FLIP sensitizes DU145 prostate cancer cells to Fas-mediated apoptosis.
Hyer ML, Sudarshan S, Kim Y, Reed JC, Dong JY, Schwartz DA, Norris JS.
Hyer ML, et al.
Cancer Biol Ther. 2002 Jul-Aug;1(4):401-6. doi: 10.4161/cbt.1.4.15.
Cancer Biol Ther. 2002.
PMID: 12432255
Item in Clipboard
Cite
Cite